



Quality



Trustworthiness



Commitment



Hardwork

**Aptus Pharma Limited**

Connecting.....Life

Since  
2011

www.aplus-pharma.com | info@aptuspharma.com | export@aptuspharma.com | +91 76004 27827

07/02/2026

The Deputy Manager  
Corporate Relationship Department  
BSE Limited  
P. J. Towers, Dalal Street,  
Mumbai – 400001

Scrip Code: 544529

ISIN: INE15XJ01010

Dear Sir/Madam,

**Sub: Intimation of Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company has prepared an Investor Presentation for dissemination to investors/analysts.

The Investor Presentation provides an overview of the Company's business operations and financial performance based on publicly available information and disclosures already made by the Company from time to time. The said presentation does not contain any unpublished price sensitive information.

In compliance with Regulation 46 of the SEBI (LODR) Regulations, 2015, the Investor Presentation will also be made available on the Company's website under the "Investor Relations" section.

A copy of the Investor Presentation is enclosed herewith for your records.

Kindly take the same on record.

Thanking you,

Yours faithfully

**For Aptus Pharma Limited**

Hathi Tejash  
Maheshchandra

Digitally signed by Hathi  
Tejash Maheshchandra  
Date: 2026.02.07 15:12:28  
+05'30'

**Tejash Maheshchandra Hathi**  
**Managing Director**  
**DIN: 03151221**

Encl.: Investor Presentation







# Aptus Pharma

Connecting ....Life

*Investor Presentation*






# Safe Harbour Statement



This presentation contains forward-looking statements which may include statements relating to the Company's expected financial performance, business prospects, growth strategy and future developments. Such forward-looking statements are based on current expectations, assumptions and estimates of the management and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation is for information purposes only and does not constitute an offer, invitation or recommendation to buy, sell or subscribe to any securities of the Company.





**At Aptus:** *Quality is a Habit*

*We Deliver Quality & Innovation*  
**To Redefine Human Lives**

**Tejash Hathi**  
(Managing Director)

**Aptus Pharma Limited... Connecting Life.**

Established in 2011, Aptus Pharma has been a stalwart in the pharmaceutical sales sector, contributing significantly to healthcare. Our commitment to quality and customer satisfaction has positioned us as a trusted and dynamic player in the pharmaceutical industry. Originally rooted in multi-state operations, we have expanded our footprint internationally with a dedicated export division.






# Company *Overview*



- 15+ therapeutic Segments

50 K+ Prescription  
Every Day



- 17,721 sq. ft.,  
Central Warehouse



trusted 10 K +  
honourable Doctors





- Our Company is engaged in the business of marketing and distribution of finished pharmaceutical formulations. While the company does not own any manufacturing facilities, it operates through a contract manufacturing model. We do not own any manufacturing plants, but have entered into contract manufacturing agreements with manufacturing units under various arrangements. Of these, we have formal loan and license agreements in place with two manufacturing units. The remaining production is carried out through informal arrangements with Other manufacturers, based on purchase orders (PO).
- We provide a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuropsychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products.

# *Our Divisions*



**APTUS *WellCare***  
(Health And Personal Care Division)



  
**APTUS CD CARE**  
(Cardiac Diabetic Division)

  
**Aptus Pharma**  
(Pioneer Division)

**APTUS *Global***  
(Export Division)



# Core *Values*







## Brand *Promise*

"We committed to healthcare  
and healthcare professionals."

Aptus Pharma pledges to uphold the highest standards in contributing  
to the well-being of individuals and supporting the healthcare  
community.



**"All Products Complies  
Standard Of cGMP & WHO"**







# Business *Process*



Aptus follows a structured and strategic business process to ensure efficient operations, quality assurance, and timely delivery of its pharmaceutical products. The end-to-end process, from demand estimation to distribution, is as follows:





### **1. Demand Estimation of Product:**

The demand for each product is forecasted using a combination of historical sales and inventory data, along with predictive analysis based on market surveys. This helps in determining potential demand and planning inventory accordingly. Thereafter, the order quantity to be manufactured is finalized.

### **2. Selection of Contract Manufacturer:**


Our Company selects the contract manufacturer based on a combination of factors, including quality of raw materials, pricing competitiveness, delivery timelines, past performance and possession of the required regulatory approvals. Preference is given to manufacturers with whom the company has a positive prior working relationship.

### **3. Issuance of Purchase Order:**

Once a manufacturer is selected, our company issues a formal purchase order specifying the quantity to be manufactured, required composition, material specifications, packaging standards, production instructions, and quality standards based on the quotations received from the manufacturers. This document serves as the basis for initiating the production process.







#### **4. Manufacturing of Products:**

Based on the approved specifications and provided schedule, the contract manufacturer initiates the production process. The responsibility of sourcing raw materials rests with the contract manufacturer. To maintain transparency and product integrity, Manufacturers are required to source materials themselves and furnish quality certificates confirming the authenticity and compliance of the inputs used. All production is carried out at facilities certified with WHO-GMP and ISO standards, ensuring adherence to stringent pharmaceutical manufacturing protocols.

#### **5. Quality Checks:**

Post-manufacturing, the contract manufacturer delivers the finished products along with a batch-wise Quality Certificate. This certificate confirms compliance with the predefined quality parameters and regulatory requirements. These tests are conducted in collaboration with certified and accredited laboratories, ensuring independent and credible validation of product integrity.

#### **6. Warehousing, Marketing and Distribution:**

Our Company stores the finished products at its rented 17,721 sq. ft central warehouses in Ahmedabad, and from there we undertake the marketing and distribution of the products through our robust and well-established distribution network. Product rollout is aligned with market demand and distributor orders to ensure optimal reach and sales execution.




- 
- Anti - Infectives
  - Antacids & PPI
  - G.I. Medicines
  - Anti -Allergic
  - Respiratory Medicine

- Nutritional Supplements
- Anti-Inflammatory
- Pain Management
- Neuropsychiatric Medicine



## Range of *Solutions*

- 
- Lipid-Lowering Medicine
  - Anti-Hypertensives & Cardiovascular Medicine
  - Antidiabetic Medicine

- Uro Care
- Wellness Product
- Ayush Products
- Oct Products
- Skin Care Products
- Hair Care Products



# Leading *Perception* *Brands*

**Chilkul-20**  
Rabeprazole 20mg  
Tablets

**Chilkul-E40**  
Esomeprazole 40mg  
Tablets

**Chilkul-ED 40**  
Esomeprazole 40mg +  
Domperidone 30mg (SR)  
Capsules

**Chilkul-DSR**  
Rabeprazole 20mg +  
Domperidone 30mg (SR)  
Capsules

**Chilkul-RAFT**  
Each 5ml contains:  
Sodium Alginate 250mg + Sodium Bicarbonate 133.5mg + Calcium Carbonate 80mg  
Suspension

**Dolotus-SP**  
Aceclofenac 100mg +  
Paracetamol 325mg + Serratiopeptidase 15mg  
Tablets

**Bactiklin-200**  
FILM COATED Tablets  
Cefpodoxime 200mg

**Faxiking-200/400**  
Rifaximin 200mg / 400mg  
Tablets

The Terminator  
**Klaviking-625+**  
Amoxicillin 500mg +  
Clavulanic Acid 125mg +  
Lactic Acid Bacillus 60 Million Spores  
Tablets

**Koltus-AB 200**  
Acebrophyline 200mg (SR)  
Tablets

**Koltus-D**  
Each 5ml contains:  
Dextromethorphan HBr 15mg +  
Chlorpheniramine Maleate 2mg + Phenylephrine 5mg  
Syrup

**Koltus-PRO**  
Each 5ml contains:  
Levoproparsine Fendizeate 35.4mg  
(Eq. to Levoproparsine HCL 20mg)  
Suspension

**Koltus-M<sup>TM</sup>**

Montelukast 10mg +  
Levocetirizine 5mg **Tablets**

A complete nutritional supplement

**Nutritus<sup>®</sup>** **Tablets**

Multivitamin, Multimineral, Biotin With  
Grape Seed Extract

**Nutritus<sup>®</sup> DM**

Methylcobalamin 1500mcg + **Tablets**  
Folic Acid 5mg + Pyridoxine 3mg +  
Vitamin D3 1000iu

**Pgtus-Total**

Pregabalin 75mg (SR) + **Bilayered**  
Nortriptyline 10mg + **Tablets**  
Methylcobalamin 1500mcg

**Vomitus-MD**

Ondansetron 4mg **Mouth dissolving**  
**Tablets**

A Broad spectrum Antimicrobial

**Zimking-200+**

Cefixime 200mg + **Tablets**  
Lactic Acid Bacillus 2.5 Billion Spores

**Aptifresh-MD**

**Mouth Dissolving Tablets**  
Clonazepam 0.5mg

**Jugsi-100**

**Tablets**  
Sitagliptin 100 mg

**Jugempa-M<sup>5/500</sup>** **Tablet**

Empagliflozin IP 5mg + Metformin  
Hydrochloride IP 500mg

**Telbira-40**

Telmisartan 40mg **Tablets**

**Telbira-AM**

Telmisartan 40mg + Amlodipine 5mg **Tablets**

**Rozutus-Gold 20**

Rosuvastatin 20mg + Aspirin 75mg + **Capsules**  
Clopidogrel 75mg

**VONKUL<sup>TM</sup> 10**

Vonoprazan 10mg **Tablets**


**VONKUL<sup>TM</sup> 20**

Vonoprazan 20mg **Tablets**





# OTC & *Wellness* *Products*





## *Quality* Policy

### **At aptus "Quality is Habit."**

Our stringent quality measures encompass every stage, from raw material procurement to finished products. Employing cutting-edge methodologies such as HPLC, we meticulously conduct comprehensive batch-to-batch analysis. These rigorous tests encompass compound assay, disintegration, dissolution, and stability tests. friability tests, equal drug distribution tests, and uniformity of content tests and other critical assessments, ensuring that each product meets and surpasses stringent quality benchmarks. We strictly adhere to good distribution practices at all levels, ensuring the highest pharmaceutical manufacturing and distribution standards.



*Quality  
Parameters*  
for each  
Batch

Compound Assay



Impurity  
Compliance



Dissolution And  
Distintegration  
Profile



Hardness  
Test



U O C (Uniformity  
of Content)



Microbiology  
Study



Related Substance  
Compliance



Friability and  
Ph Level



# Our *Esteemed Manufacturers*



- Our Loan License Manufacturing Facility



- Our Esteemed Contract Manufacturers of Our OTC Brands



- Our Esteemed Contract Manufacturing of Our Brands





# *Infrastructure* Details



## **A Robust Contract Manufacturing Ecosystem**

Aptus Pharma works with multiple manufacturing partners, many of whom have been associated with the company for over many years. These long-standing relationships are built on consistent performance, transparent quality checks, and mutual trust. Before finalising any manufacturer, Aptus conducts comprehensive due diligence, evaluating certifications, regulatory compliance, production capacity, delivery reliability, and historical quality performance. Only manufacturers that meet stringent internal benchmarks are approved.




### **Storage & Dispatch**

As part of our commitment to quality and streamlined processes, we have developed an 18,000 sq. ft. central warehouse for Domestic & Export supply.


### **Quality Control**

Affiliated certified labs for batch to rigorous quality assurance.






# Our *Facilities*



 **Ahmedabad**



## Ahmedabad



## Rajkot








# Proposed Corporate Office in Rajkot

**2205.31Sq.ft.**







**Aptus Pharma Limited**  
Connecting.....Life

**एप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस बढ़ाया, कॉस्मेटिक पोर्टफोलियो को मजबूत किया**

**एप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस बढ़ाया, कॉस्मेटिक पोर्टफोलियो को मजबूत किया**

गुजरात: एप्टस फार्मा लिमिटेड ने अपने डेडिकेटेड एप्टस वेल केयर डिवाइजन के तहत गुजरात में अपने ओटीसी बिजनेस के बड़े विस्तार की घोषणा की है, जो कंपनी के स्ट्रैटेजिक ग्रोथ प्लान में एक चरण है।

यह विस्तार केस केयर, बॉडी और स्किन केयर और हेयर केयर जैसे हाई-डिमांड कॉन्स्यूमर कैटेगरी पर फोकस करता है। यह डिवाइजन टिमग्लो, केरावा और शिरोविटा जैसे फ्लैगशिप ब्रांड्स से पारदर्शिता, जिनसे खास मार्केट में मजबूत कॉन्स्यूमर अपील मिलने की उम्मीद है। अपनी ओटीसी स्ट्रैटेजी के हिस्से के तौर पर, एप्टस फार्मा लिमिटेड ओटीसी और कॉस्मेटिक सेगमेंट में अपनी पकड़ और मजबूत करने की योजना बना रहा है। कंपनी हाइजीन केयर, पेन रिलीफ और ओरल केयर में नए लॉन्च के साथ अपने प्रोडक्ट पोर्टफोलियो को बढ़ाने की तैयारी कर रही है, जिसमें टिमग्लो डिटॉक्स और केरावा शिरोविटा जैसे आने वाले

एप्टस फार्मा लिमिटेड एक तेजी से बढ़ती ओटीसी और पर्सनल केयर मार्केट में एक बड़ा हिस्सा हासिल कर सकेगी। इस डेवलपमेंट पर फोकस करते हुए, एप्टस फार्मा लिमिटेड के मैनेजिंग डायरेक्टर, मित्तल तेजस हाथी ने कहा: “कंपनी के ओटीसी बिजनेस का जवाबदा हिमांशु वाला कॉन्स्यूमर कैटेगरी में विस्तार — एप्टस फार्मा लिमिटेड को गुजरात के तेजी से बढ़ते ओटीसी और पर्सनल केयर मार्केट में एक बड़ा हिस्सा हासिल करने के लिए मजबूती से तैयार करता है।”

एप्टस फार्मा लिमिटेड के बारे में एप्टस फार्मा लिमिटेड एक तेजी से बढ़ती फार्मास्यूटिकल कंपनी है जो कई थेराप्यूटिक एरिया में काम कर रही है। यह एक मल्टीप्ल डिस्ट्रीब्यूशन और डेडिकेटेड सेल्स, का सपोर्ट है। कंपनी अपने लॉन्ग-टर्म स्ट्रैटेजिक रोडमैप के हिस्से के तौर पर स्पेशलाइज्ड और क्रॉनिकल थैरापी सेगमेंट में अपनी मौजूदगी को मजबूत करता जारी रखे हुए है।

# Announcements

## Aptus Pharma Expands OTC Presence in Gujarat

Ahmedabad, The expansion focuses on high-demand consumer categories, including face care, body and skin care, and hair care. The division will be driven by flagship brands such as Timglo, Kerava, and Shirovita, which are expected to deliver strong consumer traction across key markets. As part of its forward-looking strategy, Aptus Pharma Limited plans to further strengthen its footprint in the OTC and cosmeceutical segment. The company is preparing to broaden its product portfolio with new launches in hygiene care, pain relief, and oral care, along with upcoming SKUs such as Timglo Detox and Kerava Shea Moisturizer. To support this

expansion, Aptus Pharma Limited is enhancing its field force and distributor network, aiming to place its OTC product range in a substantially larger number of medical stores across Gujarat. This strategic move positions Aptus Pharma Limited to capture a growing share of Gujarat’s rapidly evolving OTC and personal care market. Commenting on this development, Mr. Tejas Hathi, Managing Director of Aptus Pharma Limited, stated: “The expansion of the Company’s OTC business across high-demand consumer categories strongly positions Aptus Pharma Limited to capture a larger share of Gujarat’s rapidly advancing OTC and personal care market.”

## Accelerating growth

Aptus Pharma expands OTC presence in Gujarat, strengthening cosmeceutical portfolio

Aptus Pharma Limited is a growing pharmaceutical company operating across multiple therapeutic areas, supported by a robust distribution network and dedicated sales force. The company continues to strengthen its presence in specialty and chronic therapy segments as part of its long-term strategic roadmap.

Tejas Hathi, the managing director, states, “The expansion of our company’s OTC business across high-demand consumer categories strongly positions us to capture a larger share of Gujarat’s rapidly advancing OTC and personal care market.”

## एप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस बढ़ाया, कॉस्मेटिक पोर्टफोलियो को मजबूत किया



**Aptus Pharma Limited**  
Connecting.....Life

**एप्टस फार्मा ने गुजरात में ओटीसी प्रेजेंस बढ़ाया, कॉस्मेटिक पोर्टफोलियो को मजबूत किया**

गुजरात: एप्टस फार्मा लिमिटेड ने अपने डेडिकेटेड एप्टस वेल केयर डिवाइजन के तहत गुजरात में अपने ओटीसी बिजनेस के बड़े विस्तार की घोषणा की है, जो कंपनी के स्ट्रैटेजिक ग्रोथ प्लान में एक बड़ा टिमग्लो, केरावा और शिरोविटा जैसे फ्लैगशिप ब्रांड्स से पारदर्शिता, जिनसे खास मार्केट में मजबूत कॉन्स्यूमर अपील मिलने की उम्मीद है। अपनी ओटीसी स्ट्रैटेजी के हिस्से के तौर पर, एप्टस फार्मा लिमिटेड ओटीसी और कॉस्मेटिक सेगमेंट में अपनी पकड़ और मजबूत करने की योजना बना रहा है। कंपनी हाइजीन केयर, पेन रिलीफ और ओरल केयर में नए लॉन्च के साथ अपने प्रोडक्ट पोर्टफोलियो को बढ़ाने की तैयारी कर रही है, जिसमें टिमग्लो डिटॉक्स और केरावा शिरोविटा जैसे आने वाले

एप्टस फार्मा लिमिटेड एक तेजी से बढ़ती ओटीसी और पर्सनल केयर मार्केट में एक बड़ा हिस्सा हासिल कर सकेगी। इस डेवलपमेंट पर फोकस करते हुए, एप्टस फार्मा लिमिटेड के मैनेजिंग डायरेक्टर, मित्तल तेजस हाथी ने कहा: “कंपनी के ओटीसी बिजनेस का जवाबदा हिमांशु वाला कॉन्स्यूमर कैटेगरी में विस्तार — एप्टस फार्मा लिमिटेड को गुजरात के तेजी से बढ़ते ओटीसी और पर्सनल केयर मार्केट में एक बड़ा हिस्सा हासिल करने के लिए मजबूती से तैयार करता है।”

एप्टस फार्मा लिमिटेड के बारे में एप्टस फार्मा लिमिटेड एक तेजी से बढ़ती फार्मास्यूटिकल कंपनी है जो कई थेराप्यूटिक एरिया में काम कर रही है। यह एक मल्टीप्ल डिस्ट्रीब्यूशन और डेडिकेटेड सेल्स, का सपोर्ट है। कंपनी अपने लॉन्ग-टर्म स्ट्रैटेजिक रोडमैप के हिस्से के तौर पर स्पेशलाइज्ड और क्रॉनिकल थैरापी सेगमेंट में अपनी मौजूदगी को मजबूत करता जारी रखे हुए है।

## એપ્ટસ ફાર્માએ ગુજરાતમાં ઓટીસીનો વિસ્તાર કોસ્મેસ્યુટિકલ પોર્ટફોલિયોને મજબૂત બનાવ્યો

અમદાવાદ: એપ્ટસ ફાર્મા લિમિટેડે તેના સમર્પિત એપ્ટસ વેલ કેર ડિવાઇઝન હેઠળ ગુજરાતમાં તેના ઓટીસી વ્યવસાયના નોંધપાત્ર વિસ્તરણની જાહેરાત કરી છે, જે કંપનીની વ્યૂહાત્મક વિકાસ યોજનામાં એક મોટું પગલું છે. આ વિસ્તરણ ચહેરાની સંભાળ, શરીર અને ત્વચાની સંભાળ અને વાળની સંભાળ સહિત ઉચ્ચ માંગવાળી આહક શ્રેણીઓ પર ધ્યાન કેન્દ્રિત કરે છે. આ વિભાગ ટિમગ્લો, કેરાવા અને શિરોવિટા જેવી ફ્લેગશિપ બ્રાન્ડ્સ દ્વારા સંચાલિત થશે, જે મુખ્ય બજારોમાં મજબૂત આહક આ ક્ષેત્રમાં પ્રતિસ્પર્ધાત્મક અપેક્ષા છે.



## Aptus Pharma Enters Fast-Growing Urology Segment

New Delhi, Aptus Pharma Limited announced a major strategic step in its business expansion, confirming its entry into the rapidly growing Urology therapy segment of the Indian pharmaceutical market.

The move is poised to strengthen the company's specialty-care portfolio and is expected to become a key contributor to its future financial performance.

This product lineup positions Aptus Pharma to capitalize on the robust demand within the segment. The Indian urology market is one of the nation's fastest-growing chronic therapy segments, currently demonstrating an annual expansion rate of approximately 9-10%.

The successful introduction and expansion of this new portfolio will be underpinned by the company's significant operational strengths, including:

A strong field-sales force capable of reaching specialists across the country.

A robust distribution network comprising over 150 PLS distributors and sub-distributors nationwide.

Commenting on the strategic development, Mr. Tejash Hathi, Managing Director of Aptus Pharma Limited, highlighted the long-term vision behind the expansion.

"Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the Company for sustained growth in the coming years," stated Mr. Hathi.

This strategic entry marks a pivotal moment for Aptus Pharma as it looks to solidify its position as a diversified specialty pharmaceutical company in the highly competitive and rapidly evolving Indian market.

## Aptus Pharma announced its strategic entry into the Urology therapy segment

Ahmedabad, The Company will soon be launching a new portfolio of products in this segment, including: Silodosin range, Tamsulosin range, Alkalizer formulations.

The introduction of these products is supported by the Company's strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India.

This new portfolio is expected to contribute significantly to the Company's

future revenue growth and profitability. The Indian urology market is one of the fastest-growing chronic therapy segments, currently expanding at approximately 9-10% annually. Commenting on this development, Tejash Hathi, Managing Director, Aptus Pharma Limited., stated: "Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the Company for sustained growth in the coming years."

એપ્ટસ ફાર્માએ વિસ્તરણના ભાગરૂપે  
યુરોલોજી થેરાપી સેગમેન્ટમાં પ્રવેશ કર્યો  
મુંબઈ. એપ્ટસ ફાર્મા લિમિટેડ વિકસતી ફાર્માસ્યુટિકલ  
કંપની છે જે બહુવિધ ઉપચારાત્મક ક્ષેત્રોમાં રોકાયેલી  
છે. જેને વ્યાપક વિતરણ નેટવર્ક અને સમર્પિત વેચાણ  
દળ દ્વારા સમર્થન આપવામાં આવ્યું છે. લાંબા ગાળાના  
વ્યૂહાત્મક વિકાસના ભાગ રૂપે ક્રોનિક કેર અને ક્રોનિક  
થેરાપી સેગમેન્ટમાં તેની ઉપસ્થિતિને વિસ્તૃત કરશે.  
ભારતીય યુરોલોજી બજાર સૌથી ઝડપથી વિકસતા  
ક્રોનિક થેરાપી સેગમેન્ટમાંનું એક છે.

## Expanding horizons

Aptus Pharma Limited has announced its strategic entry into the Urology therapy segment as part of its ongoing business expansion initiatives

The introduction of these products is supported by the company's strong field-sales force and a robust distribution network consisting of 150+ PLS distributors and sub-distributors across India. Commenting on this development, Tejash Hathi, the managing director of APL, states, "Our entry into the urology therapy segment further strengthens our specialty-care capabilities and positions the company for sustained growth in the coming years."



# Events



## Team Engagement Activities

## Giving back to Society

## Conference



## Investor Meet







## *Listing ceremony*





# *Mission Bharart*



- West Zone - March 2027
- Central Zone - March 2027
- South Zone - March 2028
- North & Northeast Zone - March 2029

- Cosmeceuticals Plant March 2028



# Awards & *Certifications*





# Key *Milestones*

2010

Incorporation of our company under the name "Aptus Pharma Private Limited".




2021-25

The Company strengthened its presence in two states with a portfolio of over 210 products across 11+ therapeutic segments. It appointed a Vice President for Domestic Sales & Marketing, launched three domestic divisions, entered the OTC and wellness segment, and shifted its operational headquarters from Rajkot to Ahmedabad to support national expansion. A centralized hi-tech depot in Ahmedabad and a strong sales and distribution network across Gujarat and West Bengal further reinforced its domestic market presence.



2011-16

In 2011 Company formally launched with 2 headquarters and 11 products at a small scale, and grew by 2016 with a product line of 50+ and approx. 25% of state-level presence.



2016-20

The company has increased its product line in acute division as well as expanding its foot prints at the state level with an increase in acute therapy products. And make the company's foundation and fundamentals strong by introducing the system and process in all divisions.



# Vision 2026-30



02

Company is eyeing horizontal and vertical expansion in next 5 years by making its strong presence PAN India.

01

Company will introduce Franchise model at Odisha with strategic tie up of local C&Fs.

03

Company will launch 450+ Products range and 25+ Therapeutic segments.

04

Company introduced mission neighbour state i.e. Goa, Rajasthan, Madhya Pradesh, Maharashtra and Mumbai, Chhattisgarh by next 3 years.

05

Company will enter in Global market and eyeing on Unregulated and Semi regulated Countries.





# Our *Management*



***Mr. Tejash  
Maheshchandra Hathi***

- Mr. Tejash Maheshchandra Hathi holds an MBA in Marketing and Management Accounting from Saurashtra University (2003) and is currently pursuing a PhD in Management from Rai University, Ahmedabad. He brings over two decades of rich experience in the pharmaceutical industry and has been associated with the Company since its inception in 2010. Initially serving as Director, he was appointed Managing Director effective January 17, 2024. In this leadership role, he is responsible for overseeing the company's day-to-day operations and shaping its strategic direction.
- In addition to his corporate responsibilities, Vice President of the Drug Marketing and Manufacturing Association. (DMMA) Executive Committee Member: Indian Drug Manufacturers Association (IDMA, Gujarat chapter), Board Member of Research, Saurashtra University



***Mr. Kapil Hasmukhbhai  
Chandarana***

- Mr Kapil Hasmukhbhai Chandarana holds a Bachelor's degree in Social Work (BSW) from Saurashtra University (2017) and an MBA in Finance from Madhyanchal Professional University, Bhopal (2023).
- He brings over 16 years of extensive experience in logistics and customs operations. From 2005 to 2021, he served as Zonal Manager at Velji Dosabhai & Sons Private Limited, where he developed strong operational and managerial expertise.
- Mr Chandarana joined the Company as a Director on August 12, 2010, and served in that capacity until April 29, 2024, onwards. He was subsequently appointed Chief Financial Officer with effect from January 1, 2025.



***Mr. Ghanshyam  
Vinubhai Pansuriya***

- Mr Ghanshyam Vinubhai Pansuriya holds a Bachelor of Science degree (2007) from Saurashtra University and a Diploma in Pharmacy (2019) from Sunrise University. Mr Pansuriya joined the Company as a Director on August 12, 2010, and served in that capacity until April 29, 2024, onwards. He was subsequently appointed Chief Executive Officer effective January 1, 2025.
- With over 15 years of experience in the pharmaceutical industry, he has held key positions that have contributed to his deep domain expertise. He began his career as a Marketing Executive at Alkem Ulticare in 2008, followed by a role as a Business Development Executive at Panacea Biotech Ltd. in 2009. He later gained valuable experience at MacLeod's Pharmaceuticals Ltd., where he further honed his skills in pharmaceutical sales and business development.
- Pansuriya joined the Company as a Director on August 12, 2010, and served in that capacity until April 29, 2024, onwards. He was subsequently appointed Chief Executive Officer effective January 1, 2025.



***Mr. Chetan  
Shantilal Lalseta***

- Mr Chetan Shantilal Lalseta, aged 48 years, is the Non-Executive Director and one of the Promoters of the Company and also a Consultant Dermatologist, Venereologist, and Cosmetologist with over 20 years of experience by profession.
- He completed his M.B.B.S. in 2001 and M.D. (Skin & V.D.) in 2003 from Saurashtra University. He practices at Shraddha Hospital, Rajkot, and is a panel consultant at Wockhardt Hospital and Sterling Hospital. He also serves as a visiting faculty member at multispecialty hospitals in Rajkot.





***Mr. Riddhish  
Natwarlal Tanna***

- Mr. Riddhish Natwarlal Tanna, aged 50 years, is the Non-Executive Director and one of the Promoters of the Company and also a homeopathic practitioner and healthcare management professional with experience in academic and administrative roles. He holds a Diploma in Homeopathic Medicine & Surgery (D.H.M.S.) from the Homeopathic Council of Homeopathic System of Medicine, Gujarat, an M.D. in Homeopathy from Sardar Patel University, and an MBA in Hospital Management from Sarvepalli Radhakrishnan University, Bhopal.
- He has also completed certifications in healthcare quality implementation from the National Board of Quality Promotion and the Health Sector Skill Council of India. Dr. Tanna do his own Practice under the name of his sole proprietorship of “Sadguru Clinic” since 1997 and possessed more than 2 decades of experience in Homoeopathic System of Medicine Practice.



***Mr. Nirav J. Pandya***

- Mr Nirav J. Pandya is the Vice President of Aptus Pharma Limited, responsible for overseeing Pan-India operations. With a distinguished career spanning over 27 years in the pharmaceutical industry, he brings deep expertise in sales leadership, team development, and strategic business expansion.
- He holds a Bachelor of Science degree in Chemistry from Navyug Science College, Gujarat University (1995–1998). Mr Pandya began his career as a Medical Representative at Zydus Cadila Healthcare and went on to hold progressively senior roles at Glenmark Pharmaceuticals and J.B. Chemicals & Pharmaceuticals Ltd., advancing from Area Manager to Regional Sales Manager.
- In 2021, he joined Aptus Pharma Limited, where he currently leads the company’s nationwide sales strategy. His strong people management capabilities, financial insight, and ability to lead high-performing teams have been instrumental in driving consistent growth and performance.




TEJASH HATHI,  
MANAGING DIRECTOR

## *Leadership Speak*

Contributing Towards People's Healthcare through providing high quality, reliable and sustainable pharmaceutical products. With this philosophy, We aim to contribute to health improvements with better treatment options by giving innovative & quality pharmaceuticals. Aptus Pharma is also committed to advancements within the field of pharmaceutical products.

*"We always believe that growth is a byproduct of committed work and quality product."*





# THANK YOU



CS Mohini Gandhi



+91 84602 06914



info@aptuspharma.com

